

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081471 A1(51) International Patent Classification*: C07D 471/04,
519/00, A61K 31/44F 68300 Saint Louis (FR). HOYER, Daniel [FR/FR]; rue
Pasteur, 10, F-68300 Saint Louis (FR).

(21) International Application Number: PCT/EP02/03624

(74) Agent: BECKER, Konrad; Novartis AG, Corporate In-
tellectual Property, Patent & Trademark Dept., CH-4002
Basel (CH).

(22) International Filing Date: 2 April 2002 (02.04.2002)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data: 0108337.7 3 April 2001 (03.04.2001) GB

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH,
PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA,
US, UZ, VN, YU, ZA, ZW.(71) Applicant (for all designated States except AT, US): NO-
VARTIS AG [CH/CII]; Lichtstrasse 35, CH-4056 Basel
(CH).(84) Designated States (regional): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN
VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT];
Brunner Strasse 59, A-1230 Vienna (AT).

Published:

— with international search report

(72) Inventors: and


(75) Inventors/Applicants (for US only): TROXLER,
Thomas, J. [CH/CII]; Senneweg 27, CH-4246 Wahlen
(CH). HURTH, Konstanze [DE/FR]; 4, impasse du Golf,For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.(54) Title: BETA-CARBOLINE DERIVATIVES AND ITS PHARMACEUTICAL USE AGAINST DEPRESSION AND ANXI-
ETY(57) Abstract: The invention provides compounds
of formula (I) wherein R1 to R5 are as defined in the
description, and their preparation. The compounds
of formula (I) are useful as pharmaceuticals.

WO 02/081471 A1

BETA-CARBOLINE DERIVATIVES AND ITS PHARMACEUTICAL USE AGAINST DEPRESSION AND ANXIETY


The present invention relates to novel β -carboline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.

More particularly the invention provides a compound of formula I



wherein

R_1 is a group of formula





wherein R_6 is (C_{1-4}) alkyl, R_7 and R_8 , independently, are hydrogen or (C_{1-4}) alkyl and X is hydrogen, (C_{1-4}) alkoxy, (C_{1-4}) alkylamino or di (C_{1-4}) alkylamino, R_2 and R_3 , independently, are (C_{1-4}) alkoxy (C_{1-4}) alkyl or (C_{3-7}) cycloalkyl (C_{1-4}) alkyl, or, provided R_1 is not an optionally substituted phenyl group, (C_{1-12}) alkyl,

- 2 -

R_4 is hydrogen, (C_{1-4}) alkyl, (C_{1-4}) alkoxy, halogen or trifluoromethyl and
 R_5 is hydrogen or (C_{1-4}) alkyl,
 in free base or acid addition salt form.

On account of the asymmetrical carbon atom(s) which is (are) present in the compounds of formula I and their salts, the compounds may appear in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures. All optical isomers and their mixtures including the racemic mixtures are part of the present invention.

The compounds of formula I and their salts may also appear in the tautomeric forms having the formulae Ia and Ib




Both tautomeric forms are part of the present invention.

Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine. The above-defined alkyl and alkoxy groups preferably represent methyl and methoxy.

In a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, whereby a compound of formula II

- 3 -



wherein R_1 , R_4 and R_5 are as defined above, is reacted with a compound of formula III



wherein R_2 and R_3 are as defined above, and the compounds of formula I thus obtained are recovered in free base or acid addition salt form.

The reaction can be effected according to known methods, e.g. as described in Example 1.

Working up the reaction mixtures according to the above process and purification of the compounds thus obtained may be carried out in accordance to known procedures.

Acid addition salts may be produced from the free bases in known manner and vice-versa.

The compounds of formula II and III are known or may be prepared according to known procedures, for example according to WO 99/64420 for the compounds of formula II.

Compounds of formula I and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro using somatostatin (somatotropin release inhibiting factor, SRIF) receptor expressing cell cultures and in animals, and are therefore useful as pharmaceuticals.

In particular the agents of the invention show high affinity to somatostatin receptors. More particularly they are selective antagonists at somatostatin ssr_3 receptors, previously called

SSTR-3 receptors (see Hoyer et al., TIPS, 1995, 16; 86-88), as determined in radioligand binding and second messenger studies [see for example K. Kaupmann et al., FEBS Letts. 1993, 331: 53-59. S. Siehler et al. Naunyn Schmiedeberg's Arch Pharmacol, 1999, 360: 488-499] where they exhibit selective affinity for $ss\tau_3$ receptors with pKd values between about 7.5 and 9.0. and act as antagonists with pKi values of about 7.5 to 9.0 (S. Siehler & D. Hoyer, Naunyn Schmiedeberg's Arch Pharmacol, 1999: 360: 510-521).

The agents of the invention are therefore useful for treatment in anxiety, depression, social phobia, panic disorders, GAD (generalized anxiety disorders), OCD (obsessive compulsive disorders), post traumatic stress disorders, somatoform disorders, personality disorders, ADHD (attention deficit and hyperactivity disorders), bipolar disorders, schizophrenia, including negative symptoms, neurodegenerative diseases such as learning/memory disorders, dementia, age associated memory impairment, senile dementia of Alzheimer's type (SDAT), for the treatment of tumours and for vascular disorders and immunological diseases, as confirmed in a range of standard tests as indicated below:

In the social exploration test at doses of about 0.01 to 10 mg/kg p.o., the agents of the invention increase social contact time of rats similarly to classical anxiolytics such as benzodiazepines e.g. chlordiazepoxide or NK1 antagonists (Vassout A, Veenstra S, Hauser K, Ofner S, Brugger F, Schilling W, Gentsch C, Regulatory Peptides. 2000; 96, 7-16).

Furthermore in the mouse intruder test [Triangle, 1982, 21: 95-105; J. Clin. Psychiatry, 1994, 55:9 (suppl. B) 4-7], the agents of the invention increase social investigation and reduce defensive ambivalence in the treated intruder mouse at doses of about 1 to about 10 mg/kg s.c., suggesting an antimanic profile similar to carbamazepine and lithium, a neuroleptic profile like clozapine and an anxiolytic profile like diazepam.

In the stress-induced hyperthermia- and the elevated plus-maze paradigm in mice [Lecci et al., Psychopharmacology 101:255-261 (1990) and Rodgers R.J. Behav. Pharmacol. 8: 477-496 (1998), respectively] the agents of the invention reduced the increase in body-temperature and increased the time spent on the open arms, respectively. They are therefore indicated for the treatment of anxiety disorders and panic disorders.

However, in contrast to benzodiazepines, the compounds of the invention do not impair memory as measured in the passive avoidance test, a paradigm in which memory formation impairment e.g. by benzodiazepines, glutamate NMDA receptor antagonists or muscarinic antagonists (Venable N; Kelly PH, Psychopharmacology; 1990: 100, 215-21) have been detected.

At doses of about 0.3 to 3 mg/kg p.o., the agents of the invention increase exploratory behaviour of mice in the open half of the half enclosed platform, a model which is predictable for anxiolytic activity (Psychopharmacology, 1986, 89:31-37). In the same half enclosed platform model, the agents of the invention, at the doses indicated above, also increase vigilance of the mice.

The compounds are therefore indicated for the treatment of depression, schizophrenia and dementia, in particular of senile dementia of the Alzheimer type (SDAT).

The agents of the invention at 0.03-3 mg/kg p.o. enhance learning/memory in mice as measured in the social recognition test similar to oxiracetam or GABA_B blockers (Thor D.H. and Holloway W.R.J. Comp. Physiol. Psychol. 1982; 96: 1000-1006. Mondadori C. et al., Behavioural Brain Research 1996, 77: 227-229). Further, the agents at 0.03-0.3 mg/kg p.o. significantly increased both recognition and discrimination indices in rats in a non-social situation using the object recognition test (ORT, Ennaceur A and Delacour J. Behav Brain Res 1988; 31: 47-59), similar to rivastigmine (Exelon®).

The compounds are therefore indicated for the treatment of cognitive disturbances and learning/memory disorders.

The positive effects on memory acquisition/retention combined with the sociotropic components displayed by the agents of the invention, suggest that these will prove useful in the treatment of ADHD and various types of dementias, including Alzheimer's disease.

Furthermore at said acute doses the agents of the invention increase aggressive behaviour (attacks, chases, bites) in the Matched Pairs Situation test in mice [Dixon et al., J. Clin. Psychiatry 1994: 55: (9) [Suppl. B] 4-7]. Since as mentioned above they additionally attenuate defensive behaviours in the intruder mouse test, the agents of the invention exhibit an

ethopharmacological profile which is very similar to that of clozapine and to some extent to that of antimanic agents (lithium, carbamazepine, valproate). They are therefore indicated for the treatment of affective disorders including bipolar disorders e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilisation is desired. In addition, the compounds are indicated in anxiety states, generalised anxiety as well as social stress and agoraphobia, as well as those behavioural states characterised by social withdrawal e.g. negative symptoms [Dixon A.K. *Brit. J. Med. Psychol.* 71: 417-445; Dixon A.K., Fisch H.U. *Neuroscience and Biobehavioural Reviews*. 1990: 23; 345-358] and post traumatic stress disorders.

The agents of the invention show antidepressant-like effects in the rat, similar to desipramine or fluoxetine when given subchronically (10-30 mg/kg, p.o.) in the forced swim test. (Porsolt, R.D. et al. *Nature*. 1977: 266, 730-732) and also produce antidepressant-like effects in the mouse, similar to fluoxetine (Porsolt, R.D. et al. *Nature* 1977: 266, 730-732). Finally, these agents, when given once per day for 14 days, (0.3-30 mg/kg p.o.), reverse both the characteristic hyper-reactivity of bulbectomised rats when first placed in a novel and stressful environment and the total activity, similar to imipramine and desipramine. (Song C and Leonard BE. *Hum. Psychopharmacol* 1994; 9: 135-146).

Collectively, this set of data suggests strong antidepressant potential for the agents of the invention. Combined with the aforementioned effects, the agents of the invention are indicated for uni- and bipolar depressive disorders, generalised anxiety disorders, post traumatic stress disorders, social phobia and anxiety, panic attacks, aggression, pre-menstrual dysphoria and autism, ADHD (attention deficit and hyperactivity disorders), schizophrenia, including negative symptoms, neurodegenerative diseases such as learning/memory disorders, dementias associated with various neurological disorders, age-associated memory impairment, and SDAT.

The agents of the invention are also effective in the treatment of various kinds of tumours, particularly of $ss\tau_3$ receptor bearing tumours, as indicated in proliferation tests with various different cancer cell lines and in tumour growth experiments in nude mice with hormone dependent tumours [see for example: G. Weckbecker et al., *Cancer Research* 1994, 54: 6334-6337]. Thus, the compounds are indicated in the treatment of, for example, cancers of the

breast, the prostate, the colon, the pancreas, the brain and the lung (small cell lung cancer) and for in vivo imaging of sst_3 receptor bearing tumours.

For all the above mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 10 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 5 to about 200 mg, preferably about 10 to about 100 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.

The agents of the invention may be administered in free form or in pharmaceutically acceptable salt form. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.

Accordingly in a further aspect the present invention provides the agents of the invention for use as pharmaceuticals, more specifically for treatment in the above-mentioned conditions, e.g. schizophrenia, depression, anxiety and bipolar disorders.

The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutically acceptable diluent or carrier. Such compositions may be formulated in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 50 mg of an agent according to the invention.

Agents of the invention may be administered by any conventional route, for example parenterally e.g. in form of injectable solutions or suspensions, or enterally, preferably orally, e.g. in the form of tablets or capsules.

The agents of the invention may alternatively be administered e.g. topically in the form of a cream, gel or the like, or by inhalation, e.g. in dry powder form.

Examples for compositions comprising an agent of the invention include, e.g. a solid dispersion, an aqueous solution, e.g. containing a solubilising agent, a microemulsion and a

suspension of an agent of the invention. The composition may be buffered to a pH in the range of e.g. from 3.5 to 9.5, by a suitable buffer.

The agents of the invention can be administered either alone or in combination with other pharmaceutical agents effective in the treatment of conditions mentioned above.

Thus, the agents of the invention can be used for the treatment of depressive symptoms in combination with: tricyclics, MAO inhibitors, SSRI's, SNRI's, NK receptor antagonists, CRF-receptor antagonists, 5HT₇ receptor-antagonists, mGlu receptor agonists/antagonist/modulators, GABA_A or GABA_{A/B} receptor agonist/antagonists or modulators, vasopressin receptor antagonists, electroconvulsive shock, sleep deprivation, or herbal medicine such as St.John's Worth.

The agents of the invention can also be used for the treatment of anxiety-symptoms in combination with: benzodiazepines including mitochondrial benzodiazepine-ligands, 5-HT_{1A} receptor agonists, SSRI's, SNRI's, NK receptor-antagonists, CRF receptor-antagonists, vasopressin receptor-antagonists, mGlu receptor agonists/antagonist/modulators, GABA_A or GABA_{A/B} receptor agonists/antagonists or modulators.

The agents of the invention can further be used for the treatment of any forms of dementia, including Alzheimer's disease (SDAT) in combination with: acetylcholine-esterase inhibitors, such as rivastigmine and donepezil, mixed acetylcholine/butrylcholine esterase-inhibitors and nicotinic- α_7 -receptor agonists.

Moreover the agents of the invention can be used for the treatment of psychotic symptoms, including positive and negative symptoms in schizophrenia and schizoid type syndromes in combination with: any typical or atypical antipsychotic, such as clozapine or haloperidol, and nicotinic- α_7 -receptor agonists.

Furthermore the agents of the invention can be used for the treatment of bipolar disorders in combination with: any antimanic agent (e.g. Lithium, Carbamazepine, Valproate) or any atypical or typical antipsychotic.

The pharmaceutical compositions for separate administration of the combination partners and for the administration in a fixed combination, i.e. a single galenical composition comprising at least two combination partners according to the invention, can be prepared in a manner known per se and are thus suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application.

In particular, a therapeutically effective amount of each of the combination partners may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as fixed combination.

Accordingly the invention also provides a combination comprising a therapeutically effective amount of an agent of the invention and a second drug substance, said second drug substance being for example for use in any of the particular indications hereinbefore set forth.

The preferred indications are schizophrenia (especially negative symptoms and cognitive impairment), depression, anxiety and affective disorders, including bipolar disorders, e.g. mania.

The preferred agent of the invention for the above-mentioned indications is the (R)-1,1-bis-ethoxymethyl-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H- β -carboline, in free base or acid addition salt form. This compound shows strong affinity for sst₃ receptors (human receptor: pK_d = 8.69; mouse receptor: pK_d = 8.30) with a selectivity of more than 400 fold over other somatostatin receptors. In the social contact assay (rat), it increases dose dependently the duration of social contacts of the "intruder" towards the "resident" at 0.01-10 mg/kg p.o. (maximal amplitude at 0.3-3 mg/kg p.o.), similarly to a single dose of chlordiazepoxide of 5 mg/kg p.o.. In the passive avoidance test at 0.1, 1 or 10 mg/kg p.o., in contrast to chlordiazepoxide at 20 mg/kg p.o., no impairment of memory formation is observed. In the social recognition test (mice), at doses between 0.03 and 3 mg/kg p.o., the compound produces a significant increase of social recognition of a familiar partner, which is indicative of enhancement of learning/memory. In the forced swim test (Porsolt), the immobility time is shortened by 30-45% on subchronic administration of 12.5-25 mg/kg p.o.

In accordance with the foregoing, the present invention also provides the use of an agent of the invention as a pharmaceutical, e.g. for the treatment of schizophrenia, depression, anxiety and bipolar disorders.

Moreover the present invention provides the use of an agent of the invention for the manufacture of a medicament for the treatment of any condition mentioned above, e.g. schizophrenia, depression, anxiety and affective disorders.

In still a further aspect the present invention provides a method for the treatment of any condition mentioned above, e.g. schizophrenia, depression, anxiety and bipolar disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.

The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected.

Example 1:**(*R*)-1,1-Dibutyl-3-(4-pyridin-4-yl-1*H*-imidazol-2-yl)-2,3,4,9-tetrahydro-1*H*- β -carboline****1. 2-Bromo-1-pyridin-4-yl-ethanone hydrobromide**

2-Bromo-1-pyridin-4-yl-ethanone hydrobromide is prepared from 1-pyridin-4-yl-ethanone in 83% yield according to a known procedure (A. Taurins, A. Blaga, J. Heterocycl. Chem. 7, 1139 (1970)).

2. [(*R*)-2-(1*H*-Indol-3-yl)-1-(4-pyridin-4-yl-1*H*-imidazol-2-yl)-ethyl]-carbamic acid *tert* butyl ester

A solution of Boc-D-tryptophan (7.00 g, 23.0 mmol) and Cs_2CO_3 (7.49 g, 23.0 mmol) in DMF (85 ml) is stirred for 30 min at room temperature. 2-Bromo-1-pyridin-4-yl-ethanone hydrobromide (6.49 g, 23.0 mmol) is added and stirring is continued at room temperature for 1 h. The solvent is removed in vacuo, the residue is resuspended in AcOEt, filtered over hyflo and evaporated. The resulting oil is taken up in xylene (290 ml), ammonium acetate (35.46 g, 460 mmol) is added and the mixture is heated for 2 h at 160° using a Dean-Stark trap. After cooling to room temperature, AcOEt (100 ml) is added and the solution is washed with sat. aq. K_2CO_3 solution and brine (100 ml each). The aqueous layers are reextracted with AcOEt (2 x 100 ml); the combined organic layers are dried over Na_2SO_4 and evaporated. MPLC (400 g silica gel, AcOEt:MeOH 95:5 to 90:10) yields 3.36 g (36%) of [(*R*)-2-(1*H*-Indol-3-yl)-1-(4-pyridin-4-yl-1*H*-imidazol-2-yl)-ethyl]-carbamic acid *tert*-butyl ester (TLC: silica gel, toluene:ethanol 5:1, R_f = 0.31).

3. (*R*)-2-(1*H*-Indol-3-yl)-1-(4-pyridin-4-yl-1*H*-imidazol-2-yl)-ethylamine dihydrochloride

[(*R*)-2-(1*H*-Indol-3-yl)-1-(4-pyridin-4-yl-1*H*-imidazol-2-yl)-ethyl]-carbamic acid *tert*-butyl ester (3.46 g, 8.58 mmol) is dissolved in a mixture of glacial acetic acid (99.5%, 25 ml) and conc. aq. HCl (37%, 2.5 ml) and the solution is stirred under argon at room temperature for 1 h. The resulting precipitate is filtered, washed with acetone and dried to give 3.04 g (94%) of (*R*)-2-(1*H*-Indol-3-yl)-1-(4-pyridin-4-yl-1*H*-imidazol-2-yl)-ethylamine dihydrochloride (TLC: silica gel, toluene:ethanol:AcOH 4:4:1, R_f = 0.18).

4. (R)-1,1-Dibutyl-3-(4-pyridin-4-yl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H- β -carboline

A mixture of the above amine dihydrochloride (1.200 g, 3.19 mmol) and 5-nonanone (0.544 g, 0.663 ml, 3.83 mmol) in n-butanol (20 ml) is refluxed at 135° for 4.5 h. Using a Dean-Stark trap, 2 ml of the solvent are distilled off, then stirring is continued at 135° for 2 h and at 100° for 15 h. After cooling to room temperature and evaporation of the solvent, AcOEt (50 ml) is added and the solution is washed with sat. aq. NaHCO₃ solution (20 ml), the aqueous layer is reextracted with AcOEt (2 x 50 ml), the combined organic layers are dried over Na₂SO₄, filtered and evaporated. After MPLC (80 g silica gel, AcOEt:triethyl amine 95:5) and recrystallization from methanol:water (80:20) (R)-1,1-Dibutyl-3-(4-pyridin-4-yl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H- β -carboline (0.806 g, 59%) is obtained as a colourless crystalline solid (mp. 200-205°, TLC: silica gel, toluene:ethanol 5:1, R_f = 0.42, ESI-MS: [M+H]⁺ = 428.2).


The following compounds of formula I wherein R₄ and R₅ are hydrogen can be prepared in analogy to Example 1.

Example	R1	R2	R3	mp. (base)	[M+H] ⁺
2	Pyridin-2-yl	Butyl	Butyl	85-105°	428.2
3	Pyridin-3-yl	Butyl	Butyl	224-229°	428.2
4	Pyrazin-2-yl	Butyl	Butyl	243°	429.2
5	[1,2,4]Triazolo[1,5- α]pyridin-6-yl	Butyl	Butyl	n.d.	468.2
6	2-Methyl-[1,2,4]triazolo[1,5- α]pyridin-6-yl	Butyl	Butyl	n.d.	482.3
7	Imidazo[1,2- α]pyridin-6-yl	Butyl	Butyl	262.5°	467.3
8	2-Methyl-imidazo[1,2- α]pyridin-6-yl	Butyl	Butyl	254-257°	481.3
9	Pyridin-4-yl	Ethoxymethyl	Ethoxymethyl	132°	432.1
10	Phenyl	Ethoxymethyl	Ethoxymethyl	92-95°	431

11	Phenyl	Cyclopropyl-methyl	Cyclopropyl-methyl	84-89°	423
12	Pyridin-4-yl	Cyclopropyl-methyl	Cyclopropyl-methyl	146-149	424
13	Phenyl	1-(2-Cyclohexyl-ethyl)-piperidin-4-yl		163-166°	494.7
14	Phenyl	6,7,8,9-Tetrahydro-5H-benzocyclohepten-7-yl		80-85°	445.5
15	Phenyl	Tetrahydro-pyran-4-yl		183-186°	385.5
16	Phenyl	3,3,5,5-Tetramethyl-cyclohexyl		101-106°	439.6
17	Phenyl	Cyclooctyl		95-100°	411.5
18	6-Methoxy-pyridin-3-yl	Butyl	Butyl	103-108°	458.6
19	1-Methyl-6-oxo-1,6-dihydro-pyridin-3-yl	Butyl	Butyl	175-180°	574.7
20	2-Methoxy-pyridin-4-yl	Butyl	Butyl	162-165°	458.6
21	2-Phenyl-thiazol-4-yl	Butyl	Butyl	95-100°	510.7
22	Benzo[1,2,5]thiadiazol-5-yl	Ethoxymethyl	Ethoxymethyl	90-95°	489.6
23	Quinoxalin-6-yl	Ethoxymethyl	Ethoxymethyl	110-116°	483.6
24	1-Methyl-6-oxo-1,6-dihydro-pyridin-3-yl	Ethoxymethyl	Ethoxymethyl	132-137°	462.5


Claims

1. A compound of formula I



wherein


R_1 is a group of formula



wherein R_6 is (C_{1-4}) alkyl, R_7 and R_8 , independently, are hydrogen or (C_{1-4}) alkyl and X is hydrogen, (C_{1-4}) alkoxy, (C_{1-4}) alkylamino or di (C_{1-4}) alkylamino, R_2 and R_3 , independently, are (C_{1-4}) alkoxy (C_{1-4}) alkyl or (C_{3-7}) cycloalkyl (C_{1-4}) alkyl, or, provided R_1 is not an optionally substituted phenyl group, (C_{1-12}) alkyl, R_4 is hydrogen, (C_{1-4}) alkyl, (C_{1-4}) alkoxy, halogen or trifluoromethyl and R_5 is hydrogen or (C_{1-4}) alkyl, in free base or acid addition salt form.

- 15 -

2. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which comprises reacting a compound of formula II



wherein R_1 , R_4 and R_5 are as defined in claim 1, with a compound of formula III



wherein R_2 and R_3 are as defined in claim 1, and recovering the resulting compound of formula I in free base or acid addition salt form.

3. The compound according to claim 1 which is (R)-1,1-bis-ethoxymethyl-3-(4-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydro-1H- β -carboline, in free base or acid addition salt form.
4. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
5. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of depression, anxiety and bipolar disorders.
6. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

7. A combination comprising a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form and a second drug substance, for simultaneous or sequential administration.
8. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of depression, anxiety and bipolar disorders.
9. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of depression, anxiety and bipolar disorders.
10. A method for the treatment of depression, anxiety and bipolar disorders in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 02/03624

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D471/04 C07D519/00 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 64420 A (GALCERA MARIE ODILE ;THURIEAU CHRISTOPHE ALAIN (FR); BIGG DENNIS C) 16 December 1999 (1999-12-16) cited in the application page 3, line 17-27 claims 1,13	1-10
A	US 5 348 958 A (KRUEGER MARTIN ET AL) 20 September 1994 (1994-09-20) column 1, line 10-21 claim 1	1-10
A	US 6 057 340 A (KELLY MICHAEL G ET AL) 2 May 2000 (2000-05-02) column 1, line 10-17 claim 1	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

16 July 2002

24/07/2002

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patenthaus 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-3040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Samsam Bakhtiary, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 02/03624

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9964420	A	16-12-1999	AU 4553699 A	30-12-1999
			CN 1308632 T	15-08-2001
			CZ 20004580 A3	12-12-2001
			EP 1086101 A1	28-03-2001
			NO 20006268 A	29-01-2001
			PL 345589 A1	17-12-2001
			WO 9964420 A1	16-12-1999
US 5348958	A	20-09-1994	DE 4118741 A1	10-12-1992
			AU 658631 B2	27-04-1995
			AU 1807492 A	10-12-1992
			CA 2087098 A1	06-12-1992
			CN 1069270 A , B	24-02-1993
			CZ 281810 B6	12-02-1997
			CZ 9203968 A3	13-10-1993
			WO 9221679 A1	10-12-1992
			EP 0541757 A1	19-05-1993
			FI 930293 A	25-01-1993
			HU 63166 A2	28-07-1993
			IE 921825 A1	16-12-1992
			IL 102116 A	18-02-1997
			JP 6500341 T	13-01-1994
			MX 9202616 A1	01-09-1993
			NZ 243014 A	27-04-1995
			PL 297839 A1	02-11-1993
			PT 100565 A	31-08-1993
			RU 2105766 C1	27-02-1998
US 6057340	A	02-05-2000	US 5698555 A	16-12-1997
			ZA 9204127 A	24-02-1993
			AU 2575399 A	16-08-1999
			CA 2317515 A1	05-08-1999
			CN 1289333 T	28-03-2001
			EP 1053235 A1	22-11-2000
			JP 2002501920 T	22-01-2002
WO			9938864 A1	05-08-1999